This is a preview of subscription content, log in via an institution to check access.
Notes
The study was initiated and funded by Astellas Pharma Global Development, Inc, US.
Colombian Pesos
Reference
Parise H, et al. Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia. PharmacoEconomics-Open : 5 Jun 2019. Available from: URL: https://doi.org/10.1007/s41669-019-0149-9
Rights and permissions
About this article
Cite this article
Mirabegron a cost-effective option for OAB treatment in Colombia. PharmacoEcon Outcomes News 830, 21 (2019). https://doi.org/10.1007/s40274-019-5972-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5972-9